Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 10/20 | 0.59 |
| ▸ | BRAF | P15056 | 2/20 | 0.51 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.51 |
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | ABL1 | P00519 | 4/20 | 0.51 |
| ▸ | EGFR | P00533 | 1/20 | 0.51 |
| ▸ | RET | P07949 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 6/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18323298 | 0.92 | KIT (0.70) | KITBRAFFGFR1KDRABL1 | |
| SCHEMBL15907210 | 0.87 | KIT (0.55) | KITBRAFFGFR1KDRABL1 | |
| SCHEMBL15907204 | 0.84 | KIT (0.79) | KITBRAFFGFR1KDRABL1 | |
| SCHEMBL15907163 | 0.84 | KIT (0.73) | KITBRAFFGFR1KDRABL1 | |
| SCHEMBL15907164 | 0.82 | KIT (0.73) | KITBRAFFGFR1KDRABL1 | |
| SCHEMBL15907165 | 0.81 | KIT (0.57) | KITBRAFFGFR1KDRABL1 | |
| SCHEMBL15907260 | 0.80 | ABL1 (0.50) | KITBRAFFGFR1KDRABL1 | |
| SCHEMBL18323147 | 0.79 | KIT (0.66) | KITBRAFFGFR1KDRABL1 | |
| SCHEMBL22772378 | 0.77 | ABL1 (0.63) | KITBRAFABL1CSF1R | |
| SCHEMBL16236572 | 0.77 | KIT (0.63) | KITBRAFFGFR1KDRABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | OBSHCHESTVO S OGRANICHENNOY OTVETSTVENNOSTYOU "FUSION PHARMA" (RU) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213592-A1 | Protein Kinase Inhibitors (Variants), Use Thereof in Treating Oncological Diseases and a Pharmaceutical Composition Based Thereon | ABL1, ABL2, MAP3K6 | KIT 577/4885BRAF 30/4885FGFR1 199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.